What this trial means for you
This study is active, not recruiting. It is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Tirzepatide, Semaglutide for type 2 diabetes, heart failure.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Patients who are new users of tirzepatide or new users of semaglutide * Patients with diagnosis of T2D and HFpEF, i.e., EF \>= 45%. * Age \>= 18 years old * Patients with continuous health plan enrollment before and including the treatment initiation date Exclusion Criteria: * Patients with missing age or sex information * Patients with type 1 diabetes mellitus, secondary or gestational diabetes * History of diabetes related complications * Patients with related chronic diseases. * History of gastrointestinal conditions. * Previous exposure to other GLP-1RA and pramlintide * Patients with prescription dispensing for both tirzepatide and semaglutide on cohort entry date
Study sites by state
Massachusetts
- Brigham and Women's Hospital, Boston
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.